loader2
Partner With Us NRI

Company details

4,169.20
4,234.00
3,655.00
5,078.80
6M Return -3.05%
1Y Return -11.83%
Mkt Cap.(Cr) 70,198.99
Volume 9,277
Div Yield 0.72%
OI
-
OI Chg %
-
Volume 9,277

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Our Research View

Trading recommendation

Call Date

07 Dec 2021

Entry Price

4,506.00

Target Price

4,465.00

Duration

Intraday

Stop Loss

4,554.00


Investment recommendation

Call Date

29 Jul 2022

Entry Price

4,100.00

Target Price

4,750.00

Duration

12-18 Month

Rapid Results

Q4FY22 Quarterly Result Announced for Dr. Reddy's Laboratories Ltd.

Pharmaceuticals company Dr. Reddy's Laboratories announced Q4FY22 results:

  • Other operating income for the year at Rs 2.8 billion compared to Rs 1 billion in FY21. The increase was on account of recognition of income towards sale of our rights relating to anti-cancer agent E7777 (denileukin diftitox) to Citius Pharmaceuticals in Q2FY22. Other operating income in Q4 is Rs 0.3 billion.
  • Net Finance income for the year at Rs 2.1 billion compared to Rs 1.7 billion in FY21. The increase is primarily on account of higher foreign exchange gain in current year as compared to FY21. Net finance income in Q4 is Rs 0.9 billion.
  • Profit before Tax for the year at Rs 32.3 billion, growth of 22%. Profit before Tax for Q4 is Rs 2.5 billion.
  • Profit after Tax for the year at Rs 23.6 billion and for Q4 at Rs 0.9 billion. The effective tax rate for the year has been 27% as compared to 34.7% in FY21 and that for the quarter has been at 64.8% as compared to 41.2% in Q4FY21. The ETR was higher on account of lower Profit before Tax, due to the impairment charge taken.
  • Diluted earnings per share for the year is Rs 141.7. Diluted earnings per share for Q4 is Rs 5.3.
  • EBITDA for FY22 at Rs 51.4 billion and the EBITDA margin is 24.0%. EBITDA for Q4 FY22 is at Rs 13.0 billion and the EBITDA margin in 23.9%.
  • Capital expenditure for FY22 is at Rs. 14.7 billion. Capital expenditure for Q4FY22 is at Rs 3.7 billion.
  • Free cash-flow for FY22 is at Rs 11.6 billion and for Q4 it is at Rs 4.8 billion.
  • Net cash surplus for the company is at Rs 15.5 billion as on March 31, 2022. Consequently, net debt to equity ratio is 0.08
  • The Board has recommended payment of a dividend of Rs 30 per equity share of face value Rs 5 each (600% of face value) for the year ended March 31, 2022.

 

Result PDF

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 19,372.50 Cr FV: 5.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 2,384.58 23,141.09
LAST 3M 49,521.50 -18,551.54
LAST 6M 129,719.68 -157,153.27
LAST 12M 215,295.98 -222,611.80

Information

  • About Company
  • Company Info
  • Listing Info
23.13
26.71%
1163.874
14.46%
11.84%

Registered Address

8-2-337 Road No 3, Banjara Hills, Hyderabad, Telangana, 500034

Tel : 91-40-49002900
Email : shares:drreddys.com
Website : http://www.drreddys.com

Registrar

Bigshare Services Pvt Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 5
Market Lot Equity Shares : 1
BSE Code : 500124
NSE Code : DRREDDY
Book Closure Date (Month) : Jul
BSE Group : A
ISIN : INE089A01023

ICICIdirect Dr Reddys Laboratories Ltd FAQ

You can buy Dr Reddys Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Dr Reddys Laboratories Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Aug 08, 2022 04:01 PM the closing price of Dr Reddys Laboratories Ltd was ₹ 4,217.65.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Aug 08, 2022 04:01 PM, the market cap of Dr Reddys Laboratories Ltd stood at ₹ 70,198.99.
The latest PE ratio of Dr Reddys Laboratories Ltd as of Aug 08, 2022 04:01 PM is 23.13
The latest PB ratio of Dr Reddys Laboratories Ltd as of Aug 08, 2022 04:01 PM is 0.28
The 52-week high of Dr Reddys Laboratories Ltd is ₹ 5,078.80 while the 52-week low is ₹ 3,655.00 .
According to analyst recommendations, Dr Reddys Laboratories Ltd has a “Buy” rating for the long term.

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE